The Single-Best Pot Stock to Buy in November 2022

Profitable pot stocks such as Green Thumb are well positioned to deliver market-beating gains to long-term investors in 2022 and beyond.

| More on:
Pot stocks are a riskier investment

Image source: Getty Images

Most investors are on the lookout for stocks that can deliver exponential returns and generate outsized gains over time. While this may seem like a sound strategy, it is extremely difficult to execute. The best way to derive market-beating returns is to buy shares of companies that are part of rapidly expanding addressable markets. One such sector is cannabis, which is forecast to grow at an enviable pace in the upcoming decade.

A report from Grand View Research estimates the global cannabis market to grow by 25% annually from US$17.8 billion in 2021 to over US$135 billion in 2030. The U.S. cannabis market is forecast to grow by 15% annually in this period.

As countries in the Americas and the European Union are looking to legalize cannabis, stocks such as Green Thumb Industries (CNSX:GTII) should deliver stellar returns to long-term investors. While Canadian marijuana stocks have grossly underperformed broader indices due to industry-wide issues, pot stocks south of the border are in much better shape.

For example, Canadian cannabis producers are wrestling with high inventory levels, massive losses, shareholder dilution, and much more. Comparatively, marijuana companies in the U.S., including Green Thumb, are reporting consistent profits and are equipped with a much stronger balance sheet.

Moreover, Green Thumb and several other U.S.-based pot stocks are listed on the CNSX, allowing Canadians to gain exposure to a rapidly growing industry.

The bull case for Green Thumb Industries

One of the largest pot stocks in the world, Green Thumb is valued at a market cap of US$3.2 billion. Green Thumb is a cannabis consumer packaged goods company and retailer. It manufactures and distributes a wide portfolio of branded cannabis products while operating national retail marijuana stores called RISE.

Green Thumb is headquartered in Illinois and has 17 manufacturing facilities and 77 retail locations in 15 states in the United States. Founded in 2014, Green Thumb increased sales from US$62.49 million in 2018 to US$893.56 million in 2021. This massive expansion in top line has allowed the company to report an operating income of US$214.8 million last year, compared to a loss of US$23.8 million in 2018.

In the quarter that ended in September, Green Thumb increased sales by 12% year over year to US$261 million, while in the first nine months of the year, top-line growth stood at US$758 million, rising 17% compared to the year-ago period. Its GAAP net income stood at US$10 million, or $0.04 per share, indicating a ninth consecutive quarter of profitability.

Analysts expect Green Thumb sales to surpass US$1 billion in 2022 and rise by 11.9% to US$1.13 billion in 2023. So, GTII stock is priced at three times forward sales and 42.5 times forward earnings, which is not too steep for a company growing at a consistent pace.

What’s next for this billion-dollar pot stock?

While cannabis is still illegal at the federal level in the United States, last month, President Joe Biden announced that the government is looking to pardon marijuana possession convictions, which is a significant step towards decriminalization of cannabis. The U.S. is also looking to remove cannabis from its list of Schedule I drugs.

Green Thumb stock is down 65% from all-time highs and is well positioned to deliver promising gains to investors in the next 10 years. Its leadership position, wide economic moat, reasonable valuation, and strong balance sheet make GTII stock a top cannabis bet right now.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool recommends Green Thumb Industries. The Motley Fool has a disclosure policy.

More on Cannabis Stocks

Pot stocks are a riskier investment
Cannabis Stocks

Is the Worst Over for Canopy Growth Stock?

Down 99% from all-time highs Canopy Growth stock has burnt investor wealth and remains a high-risk investment.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in…

Read more »

A cannabis plant grows.
Cannabis Stocks

Can Aurora Cannabis Stock Recover in 2024?

Aurora Cannabis stock is down 99% from all-time highs but remains a high-risk bet, despite its cheap valuation.

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

The Best Cannabis Stock to Buy Right Now

This cannabis stock has jumped 30% in the last few months, with even more growth on the way – all…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Down 99% From All-Time Highs, Is Canopy Growth Stock a Good Buy Right Now?

Canopy Growth stock is a high-risk investment due to its negative profit margins and challenging liquidity position.

Read more »

Marijuana plant and cannabis oil bottles isolated
Stocks for Beginners

Aurora Cannabis’ Reverse Stock Split: Is the Stock a Buy Today?

Cannabis stock Aurora (TSX:ACB) is consolidating shares once again, but what does this mean for investors?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Where Will Cannabis Stocks Be in 10 Years?

Cannabis stocks could see a huge shift upwards should marijuana be rescheduled in the U.S., but you can still buy…

Read more »